Technology

Bio-Rad’s PCR-Based Test for CML Finds FDA Approval

Global life science researcher Bio-Rad has announced that its droplet digital PCR-based test for chronic myeloid leukaemia (CML), the first of its kind, has been cleared by the FDA. The test quantifies BCR-ABL, the gene fusion which causes CML, in the blood.

“Trojan Horse” Antibody to Treat Cancers Reaches New Test Stage

Toxic antibody tisutumab vedotin (TV) has shown promise as a treatment for a number of types of advanced cancer. This “trojan horse” approach has now reached the stage of being tested on a wider variety of patients. Institute of Cancer Research and Royal Marsden NHS Foundation Trust researchers tested the drug on 147 patients to evaluate potential benefits and side effects.

Open Blockchain Workshop to Discuss Potential Technology Use Cases

The Pistoia Alliance, a global not-for-profit company working in life sciences R&D, has announced the launch of the next phase in its ongoing blockchain project. The next phase includes a workshop on 12 March 2019 open to both members and non-members which will look to develop several potential use cases to the proof-of-concept stage. It will also identify which blockchain applications will have no industry value.

Gene Drives Found to Work in Mice for First Time

Scientists working at the University of California have developed a form of gene drive to control the inheritance of multiple genes in mice. Until now, such technology has been limited to the control of inheritance in insects only.

Festival of Genomics 2019 – The State of Genomics Today

The introduction of multi-omic research, the advancement of AI and machine learning to improve nearly every aspect of sequencing and data analysis, are just some of the big changes that will only become more prevalent in the future. We spoke to Angela Douglas MBE, Scientific Director of Genetics Laboratories at Liverpool Women’s Hospital, for her opinions on the changing nature of genomics and the trends to watch out for.

Festival of Genomics 2019 – The War against Rare Diseases: An Interview with Nick Sireau

Front Line Genomics was created with a social mission after our founder lost his father to mesothelioma, a rare form of cancer commonly caused by exposure to asbestos. That’s why we thought it so important to showcase Nick Sireau, who co-founded the AKU Society to combat the disease, and is now about to finish a seven-year study into a drug which play a major part in eradicating AKU altogether.

Festival of Genomics 2019 – The Move Towards Multi-Omics

With both our own festival and the wider life sciences sector moving rapidly towards a more integrative and holistic treatment of different -omics in research and drug development, we thought we’d get Dr. Dennis Wang, Lecturer in Bioinformatics and Genomics Medicine at the NIHR Sheffield Biomedical Research Centre, to talk us through the shift towards multi-omics.